Using Real-World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic Study
29 January 2020
Pan S, Tsakok T, Dand N, Lonsdale DO, Loeff FC, Bloem K, de Vries A, Baudry D, Duckworth M, Mahil S, Pushpa-Rajah A, Russell A, Alsharqi A, Becher G, Murphy R, Wahie S, Wright A, Griffiths CEM, Reynolds NJ, Barker J, Warren RB, David Burden A, Rispens T, Standing JF, Smith CH, BADBIR Study Group, the BSTOP Study Group, the PSORT Consortium.
Clinical and Translational Science, (2020) pg 400-409
Variation in response to biologic therapy for inflammatory diseases, such as psoriasis, is partly driven by variation in drug exposure. Real‐world psoriasis data were used to develop a pharmacokinetic/pharmacodynamic (PK/PD) model for the first‐line therapeutic antibody ustekinumab. The impact of differing dosing strategies on response was explored. Data were collected from a UK prospective multicenter observational cohort (491 patients on ustekinumab monotherapy, drug levels, and anti‐drug antibody measurements on 797 serum samples, 1,590 measurements of Psoriasis Area Severity Index (PASI)). Ustekinumab PKs were described with a linear one‐compartment model. A maximum effect (Emax) model inhibited progression of psoriatic skin lesions in the turnover PD mechanism describing PASI evolution while on treatment. A mixture model on half‐maximal effective concentration identified a potential nonresponder group, with simulations suggesting that, in future, the model could be incorporated into a Bayesian therapeutic drug monitoring “dashboard” to individualize dosing and improve treatment outcomes.
Using Real-World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokinetic-Pharmacodynamic Study.
Early detection of COVID-19 infection hotspots in England using large-scale self-reported data from a mobile app
17 November 2020
COVID Symptom Study app data on symptoms and PCR test results were used to identify 35-80% of UK regions before they were subject to local lockdowns
Molecular markers are identified that predict COVID-19 outcome weeks ahead
12 November 2020
A study shows accurate prediction of COVID-19 outcome from blood protein levels recorded weeks earlier, to distinguish between those who will be asymptomatic vs severe more symptoms
Multi-centre derivation and validation of a colitis-associated colorectal cancer risk prediction web-tool
4 November 2020
A web tool has been developed that helps predict which ulcerative colitis patients have increased risk of developing colorectal cancer, to help target earlier intervention